Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s disease

Background/Aims Inflammatory bowel disease (IBD) is characterised by chronic inflammation of the gastrointestinal tract, and encompasses both ulcerative colitis (UC) and Crohn’s disease (CD). Refractory disease is common, a combination of advanced drug therapies may be required to obtain maximal eff...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Robert Gilmore, Amrutha Murali, Amirah Etchegaray, Ei Swe, Yoon-Kyo An, Jakob Begun
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Korean Association for the Study of Intestinal Diseases 2025-10-01
Serie:	Intestinal Research
Soggetti:	upadacitinib vedolizumab combination therapy ulcerative colitis crohn disease
Accesso online:	http://irjournal.org/upload/pdf/ir-2024-00174.pdf
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!